Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00008203 · ClinicalTrials.gov registry record · Phase 3
Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer
A Phase 3 study, sponsored by Herbert Irving Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00008203 is a Phase 3 study that has completed, run by Herbert Irving Comprehensive Cancer Center.
The verdict
NCT00008203, a Phase 3 study, has completed, sponsored by Herbert Irving Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Biological therapy may interfere with the growth of the cancer cells. It is not yet known which post-transplant biological therapy regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of cyclosporine and interferon gamma to that of interleukin-2 following combination chemotherapy and bone marrow or peripheral stem cell transplantation in women who have stage II or stage III breast cancer.
Interventions
- DRUG carboplatin
- DRUG cyclophosphamide
- BIOLOGICAL aldesleukin
- DRUG cyclosporine
- BIOLOGICAL recombinant interferon gamma
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-05 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00008203
The ClinicalTrials.gov registry entry for NCT00008203 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Herbert Irving Comprehensive Cancer Center, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00008203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00008203 about?
NCT00008203 is a clinical study titled "Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor ...
What is the current status of trial NCT00008203?
This trial is currently completed. It is a Phase 3 study. The study started on 1996-05. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00008203?
The interventions under investigation include: carboplatin (DRUG), cyclophosphamide (DRUG), aldesleukin (BIOLOGICAL), cyclosporine (DRUG), recombinant interferon gamma (BIOLOGICAL).
Who is sponsoring clinical trial NCT00008203?
This trial is sponsored by Herbert Irving Comprehensive Cancer Center, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.